DXCM
DEXCOM INC
NASDAQ · Healthcare · Medical - Devices · US
$88.48
+6.64%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.1B | 4.7B | 4.0B | 3.6B | 2.9B |
| Cost of Revenue | 1.9B | 1.9B | 1.6B | 1.3B | 1.0B |
| Gross Profit | 3.2B | 2.8B | 2.4B | 2.3B | 1.9B |
| Operating Expenses | |||||
| R&D Expense | 608.1M | 599.1M | 552.4M | 505.8M | 484.2M |
| SG&A Expense | 1.4B | 1.3B | 1.3B | 1.2B | 1.0B |
| General & Admin Expense | 375.6M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.0B | 1.9B | 1.8B | 1.7B | 1.5B |
| Cost and Expenses | 3.9B | 3.8B | 3.4B | 3.0B | 2.5B |
| Operating Income (EBIT) | 1.2B | 911.8M | 600.0M | 597.7M | 391.2M |
| Non-Operating | |||||
| Interest Income | 74.2M | 112.7M | 134.2M | 135.0M | 23.8M |
| Interest Expense | 13.4M | 18.3M | 19.0M | 20.3M | 18.6M |
| Net Interest Income | 60.8M | 94.4M | 115.2M | 114.7M | 5.2M |
| Other Non-Op Income/Expense | 38.6M | 176.6M | 109.0M | 112.7M | (400.0K) |
| Non-Operating Income (excl Interest) | (52.0M) | (194.9M) | (128.0M) | (133.0M) | (18.2M) |
| EBT (Pre-Tax Income) | 1.3B | 1.1B | 709.0M | 710.4M | 390.8M |
| Income Tax Expense | 271.4M | 252.1M | 132.8M | 168.9M | 49.6M |
| Bottom Line | |||||
| Net Income | 991.0M | 836.3M | 576.2M | 541.5M | 341.2M |
| Earnings from Cont. Ops | 991.0M | 836.3M | 576.2M | 541.5M | 341.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 996.7M | 847.3M | 587.7M | 554.1M | 352.2M |
| Per Share | |||||
| Basic EPS | $2.59 | $2.14 | $1.46 | $1.44 | $0.88 |
| Diluted EPS | $2.55 | $2.09 | $1.42 | $1.30 | $0.80 |
| Revenue Per Share | $13.62 | $11.95 | $9.97 | $9.38 | $7.47 |
| Shares | |||||
| Basic Shares Outstanding | 374.7M | 390.2M | 404.6M | 386.0M | 389.4M |
| Diluted Shares Outstanding | 383.5M | 405.5M | 412.7M | 425.5M | 427.5M |
| Profitability Metrics | |||||
| EBITDA | 1.6B | 1.4B | 945.7M | 916.7M | 565.3M |
| D&A | 275.0M | 251.8M | 217.7M | 186.0M | 155.9M |
| EBIT | 1.3B | 1.1B | 728.0M | 730.7M | 409.4M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026